Content deleted Content added
Ozzie10aaaa (talk | contribs) →Mechanism and classification: adjust |
Ozzie10aaaa (talk | contribs) →History: ref? |
||
Line 32:
==History==
[[Vancomycin]] was isolated in 1953 and used clinically by 1958, while [[teicoplanin]] was discovered in 1978 and became clinically-available in 1984.<ref>{{cite journal |vauthors=Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA |title=Glycopeptide antibiotics: back to the future |journal=J. Antibiot. |volume=67 |issue=9 |pages=631–44 |date=September 2014 |pmid=25118105 |doi=10.1038/ja.2014.111 |doi-access=free }}</ref> [[Telavancin]] is a semi-synthetic [[lipoglycopeptide]] derivative of vancomycin approved by FDA in 2009.{{cn}}
[[Teicoplanin]] has historically been more widely-marketed - and thus more used - in Europe compared to the U.S. It has more fatty acid chains than vancomycin and is considered to be 50 to 100 times more lipophilic. Teicoplanin also has an increased half-life compared to vancomycin, as well as having better tissue penetration. It can be two to four times more active than vancomycin, but it does depend upon the organism. Teicoplanin is more acidic, forming water-soluble salts, so it can be given intramuscularly. Teicoplanin is much better at penetrating into leukocytes and phagocytes than vancomycin.{{Citation needed|date=May 2010}}
| |||